



EUROPEAN COMMISSION
JOINT RESEARCH CENTRE
Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests¹ (DoI) form (v5, 26 January 2026)

European Commission Initiative on Colorectal Cancer (ECICC)

Please answer each of the questions below.

If the answer to any of the questions is "Yes"², please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the current ECICC activities.

If you do not disclose relevant activities of interest for the ECICC, your role may be revised.

¹ According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form

[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2016\)3301&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en)

² Answering "Yes" to the questions on this form does not automatically limit your participation in the ECICC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (i.e. any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	Pierfrancesco Franco
--------------------------	-----------------------------

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
1. Do you have current investments³ in a legal entity⁴ with an interest related to colorectal cancer which either: <ul style="list-style-type: none"> • has a value of more than 10.000 EUR, or • entitles you to a voting right of 5% or more? 	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please provide information about where the investment is placed (Name, Country, Public/Private).	[Please describe the entity and your role.]

³ **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (e.g., proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

⁴ **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
<p>2. Within the past 5 years, were you employed (remunerated post), have you had any other professional relationship with a legal entity, or held any non-remunerated post in a legal entity or any other body, with an interest related to colorectal cancer?</p> <p>A. Employment</p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> • Name, Place of the entity; • Type of the entity: public, private, etc.; • The received amounts for remunerated activities. 	[Please describe your role.]
<p>B. Consultancy, including advisory activities</p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> • Name, Place of the entity; • Type of the entity: public, private, etc.; The received amounts for remunerated activities.	Please describe your role.
<p>C. Non-remunerated post</p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> • Name, Place of the entity; • Type of the entity: public, private, etc.; 	Please describe your role.

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
D. Legal representation⁵	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> • Name, Place of the entity; • Type of the entity: public, private, etc.; 	Please describe your role.

⁵ **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

<p>3. Regarding research related to colorectal cancer within the past 5 years:</p> <p>A. Have you been an investigator in research studies on colorectal cancer?</p>	<p>Yes <input checked="" type="checkbox"/></p> <p>No <input type="checkbox"/></p>	<p>01/2021 – 12/2025</p>	<p>If yes, please specify if you have been a principal investigator. Please mention the title of each study.</p> <p>Tesio V, Benfante A, Franco P, Romeo A, Arcadipane F, Iorio GC, Bartoncini S, Castelli L. The time course of health-related Quality of Life in rectal cancer patients undergoing combined modality treatment. Clin Transl Radiat Oncol. 2024 Jul 26;48:100824. doi: 10.1016/j.ctro.2024.100824. PMID: 39161735; PMCID: PMC11332791.</p> <p>Nicosia L, Bonù ML, Angelicone I, Lunardi G, Niespolo RM, Zannetti M, Agolli L, Chiloiro G, Romano A, Jafari F, Aghili M, Ghalehtaki R, Montesi G, De Felice F, De Renzi F, Magli A, Le Guevelou J, Lupattelli M, Minniti G, Gambacorta MA, Habermehl D, Franco P, Arcangeli S, Buglione M, Alongi F, Osti MF. Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study - ATLANTIS part I. Radiother Oncol. 2025 Mar;204:110701.</p>	<p>Please describe the study, your role in the study and mention if the results of the study have been published.</p> <p>Co-investigator. Results were published</p>
--	---	--------------------------	--	--

		<p>doi: 10.1016/j.radonc.2024.110701. Epub 2024 Dec 25. PMID: 40130646.</p> <p>Benfante A, Tesio V, Franco P, Romeo A, Arcadipane F, Iorio GC, Bartoncini S, Castelli L. Trajectory and predictors of psychological distress and posttraumatic growth among rectal cancer patients undergoing combined modality treatment: An exploratory prospective study. <i>Psychol Trauma</i>. 2025 Sep;17(6):1165-1174. doi: 10.1037/tra0001835. Epub 2025 Jan 9. PMID: 39786858.</p> <p>Lupattelli M, Palazzari E, Polesel J, Chiloiro G, Angelicone I, Panni V, Caravatta L, Di Biase S, Macchia G, Niespolo RM, Franco P, Epifani V, Meldolesi E, de Giacomo F, Lucarelli M, Montesi G, Mantello G, Innocente R, Osti MF, Gambacorta MA, Aristei C, De Paoli A. Preoperative Intensified Chemoradiation with Intensity-Modulated Radiotherapy and Simultaneous Integrated Boost Combined with Capecitabine in Locally Advanced Rectal Cancer: Long-Term Outcomes of a Real-Life Multicenter Study. <i>Cancers (Basel)</i>. 2023 Dec 4;15(23):5702. doi: 10.3390/cancers15235702. PMID: 38067405; PMCID: PMC10705284.</p>	
--	--	---	--

		<p>Brignoli A, Ferrara E, Zannetti M, Loi G, Forti L, Socci C, Carriero A, Gennari A, Krengli M, Franco P. Capecitabine-Induced Ileitis during Neoadjuvant Pelvic Radio-Chemotherapy for Locally Advanced Rectal Cancer: A Case Report with Literature Review. <i>Curr Oncol</i>. 2023 Oct 10;30(10):9063-9077. doi: 10.3390/curroncol30100655. PMID: 37887555; PMCID: PMC10605187.</p> <p>Mantello G, Galofaro E, Caravatta L, Di Carlo C, Montrone S, Arpa D, Chiloiro G, De Paoli A, Donato V, Gambacorta MA, Genovesi D, Lupattelli M, Macchia G, Montesi G, Niespolo RM, Palazzari E, Pontoriero A, Scricciolo M, Valvo F, Franco P. Pattern of care for re-irradiation in locally recurrent rectal cancer: a national survey on behalf of the AIRO gastrointestinal tumors study group. <i>Radiol Med</i>. 2023 Jul;128(7):869-876. doi: 10.1007/s11547-023-01652-3. Epub 2023 Jun 26. PMID: 37365381; PMCID: PMC10317862.</p> <p>Chiloiro G, Romano A, Mariani S, Macchia G, Giannarelli D, Caravatta L, Franco P, Boldrini L, Arcelli A, Bacigalupo A, Belgioia L, Fontana A, Meldolesi E, Montesi G, Niespolo RM,</p>	
--	--	--	--

		<p>Palazzari E, Piva C, Valentini V, Gambacorta MA. Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) - A multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Study Group. Clin Transl Radiat Oncol. 2023 Jan 12;39:100579. doi: 10.1016/j.ctro.2023.100579. PMID: 36935859; PMCID: PMC10014327.</p> <p>Caravatta L, Lupattelli M, Mantello G, Gambacorta MA, Chiloiro G, DI Tommaso M, Rosa C, Gasparini L, Morganti AG, Picardi V, Niespolo RM, Osti MF, Montrone S, Simoni N, Boso C, Facchin F, Deidda MA, Piva C, Guida C, Ziccarelli L, Munoz F, Ivaldi GB, Marchetti V, Franzone P, Spatola C, Franco P, Donato V, Genovesi D; Gastrointestinal Study Group of AIRO (Italian Association of Radiation Oncology and Clinical Oncology). Treatment Volume, Dose Prescription and Delivery Techniques for Dose-intensification in Rectal Cancer: A National Survey. Anticancer Res. 2021 Apr;41(4):1985-1995. doi: 10.21873/anticancerres.14966. PMID: 33813405.</p>	
--	--	--	--

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
B. If yes, for the aforementioned research studies, did you receive support⁶?	Yes <input type="checkbox"/>	MM/YYYY	If yes, please specify:	Please mention the title of the studies you refer to.
	No <input checked="" type="checkbox"/>	– MM/YYYY	<ul style="list-style-type: none"> • the type of received support (grants, funds); • the entity which offered the support - Name, Place, type (public, private); • the received amounts (for public grants please also specify the annual budget of your home institution).	
4. Do you have membership in national or international organisations⁷, including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in colorectal cancer?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> • Name, Place; • Type: public, private, etc. (list all if more than one).	Please describe your role and the activities you were involved in specifying if you have participated in a decision-making process.

⁶ **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

⁷ **Organisation** refers to a governmental, international or non-profit organisation.

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
5. Do you have intellectual property rights (IPR)⁸ related to colorectal cancer?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	Please describe the IPR.
6. Within the past 5 years:				
A. Have you provided any expert opinion or testimony in the field of colorectal cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the activity.	Please describe the activity.
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field colorectal cancer?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the activity.	Please describe the activity.

⁸ **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
7. Do any of your immediate family members⁹ have direct interests related to colorectal cancer that could undermine your independence?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the interest.	Please describe the interest.
8. Within the past 5 years, did you take part in other activities with interests related to colorectal cancer?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the activity.	Please describe the activity.

⁹ **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published¹⁰ before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending a message as soon as possible to: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

- I hereby declare that the information disclosed in this form is true and complete to the best of my knowledge.
- I agree my DoI form to be publicly available on the JRC Healthcare Quality website, during the ECICC membership¹¹.
- I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725¹².

Name and Surname: Pierfrancesco Franco
02.02.2026

Date:

Signature:



Place: Turin, Italy

¹⁰ Personal data processing including the Declaration of Interests

<https://ec.europa.eu/dpo-register/detail/DPR-EC-00656>

¹¹ Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

¹² Protection of individuals with regard to the processing of personal data

<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725>